US Patent 10144737 Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
Patent 10144737 was granted and assigned to Jiangsu Hengrui Medicine on December, 2018 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 10144737 Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
